The FDA has issued draft guidance to reduce unnecessary animal testing in nonclinical safety assessments for certain cancer drugs.Once finalized, this would reduce the time it takes for new cancer drugs to go from discovery to patient use.

The FDA has issued draft guidance to reduce unnecessary animal testing in nonclinical safety assessments for certain cancer drugs.Once finalized, this would reduce the time it…

News, features, and commentary about cancer-related issues